Pragmatic Friday: 📉 Why NVO Looks Cheap At 12x P/E

🌞 Good Morning, Pragmatic Thinkers!

This week looked dramatic on the surface — but most of it was noise pretending to be insight.

Headlines screamed urgency, timelines were dissected, and every price move was framed like a turning point. The market loves a good story, especially when nothing truly new is happening. What trended wasn’t what mattered. And what mattered barely made a sound.

That’s the uncomfortable truth.

While attention bounced from one hot take to the next, Novo Nordisk (NVO) quietly sat in the middle of a very different setup — strong growth, expanding access to weight management, and a valuation that still reflects skepticism rather than conviction. No fireworks. No hype. Just fundamentals doing their work while sentiment lagged behind.

That disconnect is the real story this week.

In The Pragmatic Playbook, I’m stepping away from the surface-level drama to focus on NVO — not as a headline trade, but as an example of how markets often misprice durable growth when the narrative feels uncomfortable or politically noisy. This isn’t about chasing excitement. It’s about recognizing when fear and fatigue have created breathing room.

That’s the lens I want you carrying into the next stretch of the market — calm, selective, and anchored in signal over sentiment.

And before we go any further, a sincere wish to you and your loved ones: Merry Christmas and a peaceful Boxing Day. I hope the coming days bring some distance from screens, a bit of stillness, and the kind of clarity that only shows up when the noise finally fades.

🔥 Market Pulse – What Actually Mattered

🤖 Palantir’s Retail Army Meets Valuation Gravity
Palantir has become one of the poster children of 2025’s retail-powered market, where individual investors can meaningfully move sentiment and flow. The bull case is “this is a long-term platform winner.” The bear case is simpler: when a stock is priced for perfection, even strong execution can still get punished if the market decides to pay a lower multiple.

💸 Struggling To Save For Retirement? Break The Cycle In 2026
If retirement savings only happen with “whatever is left,” it usually ends up being nothing. The practical fix is to automate contributions so saving happens first, not last. The piece also leans on two levers that actually move the needle: boosting income (even temporarily) and not missing any employer match if you have one.

🏦 The Fed’s 2025 Divisions Are Rolling Into 2026
The Fed is heading into 2026 with louder internal disagreement, and that matters because markets trade on expectations as much as they trade on policy. When policymakers aren’t aligned, guidance gets murkier, and every CPI and jobs print starts to feel like a potential “reset” moment. Translation: more sensitivity, more whipsaws, and less patience for ambiguity.

TOGETHER WITH OUR PARTNER

The Future of Shopping? AI + Actual Humans.

AI has changed how consumers shop by speeding up research. But one thing hasn’t changed: shoppers still trust people more than AI.

Levanta’s new Affiliate 3.0 Consumer Report reveals a major shift in how shoppers blend AI tools with human influence. Consumers use AI to explore options, but when it comes time to buy, they still turn to creators, communities, and real experiences to validate their decisions.

The data shows:

• Only 10% of shoppers buy through AI-recommended links

• 87% discover products through creators, blogs, or communities they trust

• Human sources like reviews and creators rank higher in trust than AI recommendations

The most effective brands are combining AI discovery with authentic human influence to drive measurable conversions.

Affiliate marketing isn’t being replaced by AI, it’s being amplified by it.

Download the full report to see what this means for your brand.

🎯 The Pragmatic Playbook: Novo Nordisk - When The Market Prices Fear, Not Facts

Novo Nordisk doesn’t look exciting right now.

There’s no parabolic chart. No daily chatter. No sense of urgency in the tape. For a company delivering roughly 25% year-over-year earnings growth, about 24% revenue growth, and expanding its product footprint meaningfully, the market’s reaction has been… muted.

Almost dismissive.

At around 12x earnings, Novo is being valued like a company whose best days are behind it — not one that’s still scaling demand in one of the largest, most persistent healthcare markets in the world.

That mismatch is the story.

Because when growth accelerates and valuation compresses at the same time, it’s rarely because fundamentals suddenly broke. More often, it’s because the market is anchoring to an old narrative that no longer fits the business in front of it.

With Novo Nordisk, that disconnect is getting harder to ignore.

🧠 The Mispricing: Why The Numbers And The Narrative Don’t Match

Let’s slow this down.

Earnings growing ~25%.
Revenue growing ~24%.
Demand still strong enough to strain supply in key regions.
A new weight-management pill now approved, expanding reach beyond injectables.

And the stock trades at ~12x earnings.

That’s not how the market usually prices companies with momentum like this.

At that multiple, the market is implicitly assuming one or more of the following:

• Growth slows materially

• Margins compress

• Political pressure meaningfully caps pricing

• Competition erodes Novo’s advantage faster than expected

None of those risks are imaginary. But here’s the problem: they’re already priced in.

A 12x multiple doesn’t assume execution excellence. It assumes disappointment.

That’s where loss aversion quietly flips.

The risk here isn’t that Novo fails spectacularly.
It’s that investors wait for perfect clarity and miss the compounding while the business keeps delivering.

Markets are very good at overpaying for certainty.
They’re terrible at pricing durable growth when the story feels uncomfortable.

Right now, Novo Nordisk sits squarely in that discomfort zone.

💊 Why The Pill Approval Changes The Shape Of The Opportunity

Injectables changed the conversation around weight management.

Oral therapies change the scale.

The approval of a weight-management pill isn’t just “another product.” It removes friction — and friction is what caps adoption curves.

No needles.
Lower psychological barriers.
Easier physician conversations.
Greater appeal to patients who were never going to inject themselves.

This doesn’t replace injectables. It widens the funnel.

That’s the part many investors underestimate. The pill doesn’t need to cannibalize existing products to matter. It expands the addressable market by pulling forward demand that was previously locked out by behavior, not efficacy.

This is how categories mature.

Once friction drops, adoption becomes a logistics problem — not a persuasion problem.

From an investor’s perspective, that matters because logistics problems are solvable with capital, scale, and execution. Novo already has all three.

This isn’t about a one-quarter revenue bump.
It’s about duration.

Products that reduce friction tend to extend lifecycle value, deepen patient relationships, and increase adherence. Those dynamics don’t show up immediately in headline numbers — but they compound quietly over time.

🧬 Why Novo Is Not A Typical Pharma Stock

Most pharma stories are fragile.

They rely on one or two blockbuster drugs. They live and die by trial outcomes, patent cliffs, and binary events. When sentiment turns, the multiple collapses.

Novo Nordisk is operating under a different model.

Weight management and metabolic disease are no longer episodic treatments. They’re becoming chronic care pathways. That changes everything.

This isn’t a one-and-done prescription.
It’s an ongoing healthcare relationship.

Recurring relationships create:

• More predictable revenue

• Deeper physician trust

• Data advantages

• Institutional stickiness that’s hard to displace

This is why I don’t think of Novo as “just another GLP-1 stock.”

I think of it as infrastructure for metabolic health.

Once infrastructure is in place, growth becomes less about hype and more about throughput. The market tends to misprice this transition because it’s used to thinking in quarters, not adoption curves that play out over years.

That’s why political noise, pricing debates, and competition headlines feel louder than they should. They distract from the structural shift underneath.

🧭 How I’m Thinking About NVO As An Investor

I’m not looking at Novo Nordisk as a trade.

I’m looking at it as a mispriced compounder hiding inside a controversial narrative.

Political scrutiny will come and go.
Pricing debates will cycle.
Competitors will emerge.

But demand for effective weight-management solutions isn’t cyclical.

It’s demographic.

When I see a company growing earnings north of 20%, expanding its product ecosystem, lowering adoption friction, and still trading at a valuation that assumes trouble, I don’t rush to time an entry.

I get patient.

This is not a stock for traders who need validation every quarter.
If you need excitement to stay invested, Novo will test your patience.

But if you’re willing to think in years instead of headlines, this setup starts to look less risky — not more.

Time does the heavy lifting here. Not timing.

⚠️ The Risk That Actually Matters

Every thesis deserves a clear break condition.

The real risk to Novo Nordisk isn’t tomorrow’s competition or next month’s political headline.

It’s execution over time.

Can Novo scale supply fast enough?
Can it manage global reimbursement dynamics?
Can it maintain physician trust as adoption widens?

If execution falters meaningfully — if demand stays strong but delivery fails — the thesis weakens.

So far, Novo has shown discipline and foresight. But this is where ongoing monitoring matters. Undervaluation only works if fundamentals continue to do their job.

🧩 The Pragmatic Takeaway

When growth looks boring and valuation looks skeptical, discipline usually has an edge.

Novo Nordisk isn’t cheap because it’s broken.
It’s cheap because the market is tired of the story.

But stories fade.
Cash flows compound.

At ~25% earnings growth, ~24% revenue growth, and a ~12x multiple, the math doesn’t scream exuberance. It whispers opportunity.

Novo doesn’t need hype to work.
It needs time.

And time is the one variable the market consistently misprices — especially when discomfort replaces excitement.

That’s usually where the best long-term setups live.

Quietly.

TOGETHER WITH OUR PARTNER

Six resources. One skill you'll use forever

Smart Brevity is the methodology behind Axios — designed to make every message memorable, clear, and impossible to ignore. Our free toolkit includes the checklist, workbooks, and frameworks to start using it today.

Access the free resources

🧘The Friday Reset

It’s been one of those weeks where the market feels louder than the facts. Opinions piled up, timelines got debated, and every price move seemed to demand an emotional response. That kind of noise is exhausting, and it’s usually when investors start questioning good positions simply because they’re not being validated in real time. Fatigue has a way of making patience feel like a mistake.

Here’s the reset I’m carrying into the weekend: if it feels like you’re behind, you’re not — you’re just early. When the market slows down, real clarity speeds up. My edge doesn’t come from guessing what happens next; it comes from preparing for what happens when sentiment shifts. Hype doesn’t last, but setups do, and stillness is often where the strongest conviction is built.